Our Partners: Icagen, Inc.
Pfizer and Icagen, Inc. entered into a worldwide collaboration and licensing agreement for the discovery, development, and commercialization of compounds which modulate three specific sodium ion channels as potential new treatments for pain and related disorders. The companies will combine resources to identify compounds that target these ion channels in a global research and development collaboration.
We are enthusiastic about entering into this collaboration with Pfizer. By combining one of our multitarget ion channel pain programs with similar programs at Pfizer, we believe that together our scientific teams will be well positioned to capitalize upon this exciting therapeutic opportunity... It is a distinct privilege to join forces with Pfizer as we continue to advance our mission of discovering and developing novel medications that address areas of real medical need.
—P. Kay Wagoner, Ph.D., President and Chief Executive Officer, Icagen
"Pfizer is committed to flexible, transparent and mutually beneficial long-term relationships with its partners. By joining forces, we can bring quality therapies to patients worldwide. Let's work together for a healthier world."
—Bill Ringo, Senior Vice President,
Worldwide Business Development
Strategy & Innovation
- Contact Us
- Investors
- Sitemap
- Careers
- Business to Business
- Terms of Use
- Global Network
- Privacy Policy
Copyright © 2002–2009 Pfizer Inc. All rights reserved. This information is intended only for residents of the United States. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries. Pfizer Inc is a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.
